NASDAQ:HSCS

HeartSciences Q2 2026 Earnings Results & Report

HeartSciences logo
$2.06 -0.02 (-0.96%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$2.24 +0.18 (+8.79%)
As of 07:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HeartSciences beat analyst expectations on both earnings and revenue in its Q2 2026 results, released December 15, 2025. The company reported EPS of -$0.85 versus the -$0.90 consensus estimate, while revenue of $2.42 million topped the $1 thousand estimate by $2.42 million.

Earnings Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

HeartSciences EPS Results

Actual EPS
-$0.85
Consensus EPS
-$0.90
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

HeartSciences Revenue Results

Actual Revenue
$2.42 million
Expected Revenue
$1 thousand
Beat/Miss
Beat by +$2.42 million
YoY Revenue Growth
N/A

Upcoming Earnings

HeartSciences' Q2 2027 earnings is estimated for Monday, December 21, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, December 16, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

HeartSciences Q2 2026 Earnings FAQ

HeartSciences (NASDAQ:HSCS) reported earnings of -$0.85 per share for Q2 2026, beating the consensus estimate of -$0.90. The report was announced on Monday, December 15, 2025.

HeartSciences reported revenue of $2.42 million for Q2 2026, against a consensus estimate of $1 thousand.

HeartSciences' next earnings date is estimated for Monday, December 21, 2026. MarketBeat tracks confirmed and estimated earnings dates for HeartSciences on the company's earnings history page.

HeartSciences Earnings Headlines

This Could Be the Biggest Monetary Shift in 50 Years
The U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trades above $4,000 today. That gap means Washington's books show about $11 billion in gold that is actually worth more than $1 trillion. A bill in Congress would require repricing those reserves at market value. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free, according to the 2026 Gold and Silver Guide.tc pixel
See More HeartSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HeartSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HeartSciences and other key companies, straight to your email.

About HeartSciences

HeartSciences (NASDAQ:HSCS) develops medical technology intended to help healthcare professionals detect heart conditions using electrocardiograms (ECGs). The company combines ECG testing with software-based analysis to support the assessment of cardiac function.

Its MyoVista wavECG device is designed to perform standard ECG testing while also analyzing the heart’s electrical signals for information that may help identify dysfunction, including diastolic dysfunction. The company’s offerings are aimed at clinical settings where ECGs are used to evaluate patients’ heart health.

HeartSciences focuses on developing and commercializing these technologies for healthcare providers. Its products are intended to complement existing diagnostic workflows; medical professionals determine how results are interpreted and used in patient care.

View HeartSciences Profile